found that tamoxifen could promote ERα36 binding and the activation of estrogen-responsive elements in the ALDH1A1 promoter, to increase the transcription of ALDH1A1, which accounted for the resistance to hormone therapy and metastasis of breast cancer (64). The gene discussed is ALDH1A1; the disease is breast carcinoma.